Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 153

Sort by

Sort Order Select

Journal Articles

Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Jason A. Dubovsky, PhD, Julie Rytlewski, PhD, Lin Yang, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 503.

https://doi.org/10.1182/blood-2019-127603

Published: 2019

Journal Articles

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-Cell Malignancies

Feng Zhu, Yongxian Hu, MD, Wei Guoqing, He Huang, Wenjun Wu, MD

Blood (2019) 134 (Supplement_1): 3220.

https://doi.org/10.1182/blood-2019-129649

Published: 2019

Journal Articles

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Blood (2019) 134 (Supplement_1): 4074.

https://doi.org/10.1182/blood-2019-131300

Published: 2019

Journal Articles

Pretransplant Risk Factors for Calcineurin Inhibitor-Induced Encephalopathy and Limbic Encephalitis Following Allogeneic Hematopoietic Cell Transplantation

Nao Tanizawa, MD, Hideo Koh, MD PhD, Hiroshi Okamura, MD PhD, Koh Shiro, MD PhD, Satoru Nanno, MD PhD, Mitsutaka Nishimoto, MD PhD, Asao Hirose, MD PhD, Mika Nakamae, MD PhD, Yasuhiro Nakashima, MD PhD, Takahiko Nakane, MD PhD, Masayuki Hino, MD PhD, Hirohisa Nakamae, MD PhD

Blood (2019) 134 (Supplement_1): 4492.

https://doi.org/10.1182/blood-2019-124264

Published: 2019

Journal Articles

First-in-Human Study of ET019003, a Next Generation Anti-CD19 T-Cell Therapy, in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

Pengcheng He, Hong Liu, Haibo Liu, Mina Luo, Hui Feng, Qijing Li, Qi Chang, Bingyi Shi, Cheng Liu

Blood (2019) 134 (Supplement_1): 2870.

https://doi.org/10.1182/blood-2019-131414

Published: 2019

Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Giuseppe Gritti, MD PhD, Anna Sureda, MD PhD, Maria Jose Terol, Martin JS Dyer, DPhil, Gloria Iacoboni, MD, William Townsend, MRCP,MDFRCPath, Marina Bacac, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Angelika Lahr, PhD, Katharina Lechner, MD, Tom Moore, MBChB, Peter N Morcos, PharmD, Anesh Panchal, MSc, Martin Weisser, MD, Ciel De Vriendt

Blood (2019) 134 (Supplement_1): 2871.

https://doi.org/10.1182/blood-2019-123978

Published: 2019

Journal Articles

Patient Specific Comorbidities Impact Overall Survival in Myelofibrosis

Andrew Sochacki, MD, Cosmin Adrian Bejan, PhD, Shilin Zhao, PhD, Travis Spaulding, MD, Shannon Stockton, MD, Alexander Silver, Dixon Dorand, MD PhD, Siwei Zhang, PhD, Thomas Stricker, MD PhD, Yaomin Xu, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2959.

https://doi.org/10.1182/blood-2019-121513

Published: 2019

Journal Articles

The Risk of Hepatitis B Reactivation Is Controllable in Patients with Concomitant Hepatitis B Virus Infection during Chimeric Antigen Receptor T-Cell Therapy

Wei Liu, Rui Lv, Wenyang Huang, Hong Liu, Shuhui Deng, MD, Shuhua Yi, MD, Lulu Lv, Jianxiang Wang, MD, Lugui Qiu, MD PhD, Dehui Zou, MD

Blood (2019) 134 (Supplement_1): 2913.

https://doi.org/10.1182/blood-2019-126635

Published: 2019

Journal Articles

Impact of Bridging Chemotherapy on Clinical Outcomes of CD19 CAR T Therapy in Relapse/Refractory Diffuse Large B- Cell Lymphoma in Real World Experience

Jérôme Paillassa, MD, Laetitia Vercellino, Roberta Di Blasi, Sophie Bernard, Hannah Moatti, MD, Côme Bommier, Matteo Guerra, Veronique Meignin, Sylvie Chevret, Catherine Thieblemont, MD PhD

Blood (2019) 134 (Supplement_1): 2886.

https://doi.org/10.1182/blood-2019-129421

Published: 2019

Journal Articles

Hematological Presentation and Change in Clinical Phenotype during Follow-up in Pearson Syndrome

Ayami Yoshimi, MD PhD, Sarah C Grünert, MD, Holger Cario, MD PhD, Ute Gross-Wieltsch, MD, Udo Kontny, MD, Kyogo Suzuki, MD PhD, Stephan Lobitz, MD, Helen Wagner, MD, Irene Schmid, MD, Daniela Karall, MD, Arndt Borkhardt, MD, Miriam Erlacher, Peter Noellke, MPH, Charlotte M. Niemeyer, MD

Blood (2019) 134 (Supplement_1): 3746.

https://doi.org/10.1182/blood-2019-125199

Published: 2019

Journal Articles

Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

A. Samer Al-Homsi, MD, Enkhtsetseg Purev, MD PhD, Philippe Lewalle, Maher Abdul-Hay, MD, Daniel A Pollyea, MD, Adriano Salaroli, MD, Thomas Lequertier, Erik Alcantar-Orozco, MD, Fabian Borghese, Caroline Lonez, PhD, Nathalie Braun, Florence Renard, Anne Flament, MD, Ine Moors, MD, Tessa Kerre

Blood (2019) 134 (Supplement_1): 3844.

https://doi.org/10.1182/blood-2019-128267

Published: 2019

Journal Articles

Acute Myeloid Leukemia and Cirrhosis: Trends in Utilization of Induction Chemotherapy, Rate of Hospitalizations and Mortality

Giulia Petrone, MD MBBS, Shivani Handa, MBBS, Kamesh Gupta, MBBS, Ahmad Khan, MD, Sridevi Rajeeve, MD

Blood (2019) 134 (Supplement_1): 3864.

https://doi.org/10.1182/blood-2019-126177

Published: 2019

Journal Articles

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Marc Schwartz, MD, Lloyd E. Damon, MD, Deepa Jeyakumar, MD, Caitlin L. Costello, MD, Dimitrios Tzachanis, MD PhD, Gary J. Schiller, MD, Jesika Reiner, MPH, Matthew J. Wieduwilt, MD PhD

Blood (2019) 134 (Supplement_1): 3880.

https://doi.org/10.1182/blood-2019-131061

Published: 2019

Journal Articles

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Scott R. Goldsmith, MD, Sana Saif Ur Rehman, MD, Cara Lunn Shirai, PhD, Ravi Vij, MBBS, John F. DiPersio, MD PhD

Blood (2019) 134 (Supplement_1): 2325.

https://doi.org/10.1182/blood-2019-124176

Published: 2019

Journal Articles

Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

Blood (2019) 134 (Supplement_1): 2625.

https://doi.org/10.1182/blood-2019-130370

Published: 2019

Journal Articles

Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel

Ajeet Gajra, MD FACP, Marjorie E Zettler, PhD MPH, Eli G Phillips Jr., PharmD, JD, Andrew J Klink, PhD MPH, Jonathan K. Kish, PhD MPH, Sonam Mehta, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 1952.

https://doi.org/10.1182/blood-2019-129593

Published: 2019

Journal Articles

CD19-Directed Fast CART Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia: From Bench to Bedside

Cheng Zhang, Jiaping He, Li Liu, Jishi Wang, PhD, Sanbin Wang, Ligen Liu, Lei Gao, Li Gao, Yao Liu, Peiyan Kong, Jia Liu, Yu Han, Yongliang Zhang, Zhe Sun, Xun Ye, Yan He, Lianjun Shen, MD PhD, Wei Cao, Xi Zhang

Blood (2019) 134 (Supplement_1): 1340.

https://doi.org/10.1182/blood-2019-128006

Published: 2019

Journal Articles

Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Larger B Cell Lymphoma: An Open-Label, Single-Arm, Phase Ⅰ/Ⅱ Trial

Wei Sang, MD, Ming Shi, Jingjing Yang, Jiang Cao, MD, Linyan Xu, PhD, Dongmei Yan, Xuguang Song, Cai Sun, Depeng Li, Feng Zhu, Zhenyu Li, MD, Junnian Zheng, Jianlin Qiao, PhD, Kailin Xu, MD

Blood (2019) 134 (Supplement_1): 1590.

https://doi.org/10.1182/blood-2019-127640

Published: 2019

Journal Articles

An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk

Catherine Diefenbach, MD, Sarit Assouline, MD, Francesc Bosch, MD PhD, Chan Y. Cheah, Won Seog Kim, MD PhD, Matthew J Matasar, MD, Carlos Panizo, MD PhD, Dok Hyun Yoon, MD PhD, Brendan Bender, PhD, Genevive Hernandez, PhD, Chi-Chung Li, PhD, Bruce McCall, MD, Carol O'Hear, MD PhD, Michael C Wei, MD PhD, Shen Yin, PhD, Kasra Yousefi, MSc, Antonia Kwan, MD PhD MRCPCH, Loretta J. Nastoupil, MD MSc

Blood (2019) 134 (Supplement_1): 4728.

https://doi.org/10.1182/blood-2019-123757

Published: 2019

Journal Articles

Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States

Michael S Broder, MD MSHS, Qiufei Ma, PhD, Tingjian Yan, PhD, Eunice Chang, PhD, Lamis K. Eldjerou, MD, Yanni Hao, PhD, David Kuzan, MD, Jie Zhang, PhD

Blood (2019) 134 (Supplement_1): 4719.

https://doi.org/10.1182/blood-2019-122587

Published: 2019

NARROW

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-Cell Malignancies

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Pretransplant Risk Factors for Calcineurin Inhibitor-Induced Encephalopathy and Limbic Encephalitis Following Allogeneic Hematopoietic Cell Transplantation

First-in-Human Study of ET019003, a Next Generation Anti-CD19 T-Cell Therapy, in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Patient Specific Comorbidities Impact Overall Survival in Myelofibrosis

The Risk of Hepatitis B Reactivation Is Controllable in Patients with Concomitant Hepatitis B Virus Infection during Chimeric Antigen Receptor T-Cell Therapy

Impact of Bridging Chemotherapy on Clinical Outcomes of CD19 CAR T Therapy in Relapse/Refractory Diffuse Large B- Cell Lymphoma in Real World Experience

Hematological Presentation and Change in Clinical Phenotype during Follow-up in Pearson Syndrome

Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Acute Myeloid Leukemia and Cirrhosis: Trends in Utilization of Induction Chemotherapy, Rate of Hospitalizations and Mortality

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib

Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel

CD19-Directed Fast CART Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia: From Bench to Bedside

Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Larger B Cell Lymphoma: An Open-Label, Single-Arm, Phase Ⅰ/Ⅱ Trial

An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk

Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only